dc.contributor.author | Lunnon, K | |
dc.contributor.author | Keohane, A | |
dc.contributor.author | Pidsley, R | |
dc.contributor.author | Newhouse, S | |
dc.contributor.author | Riddoch-Contreras, J | |
dc.contributor.author | Thubron, EB | |
dc.contributor.author | Devall, M | |
dc.contributor.author | Soininen, H | |
dc.contributor.author | Kłoszewska, I | |
dc.contributor.author | Mecocci, P | |
dc.contributor.author | Tsolaki, M | |
dc.contributor.author | Vellas, B | |
dc.contributor.author | Schalkwyk, L | |
dc.contributor.author | Dobson, R | |
dc.contributor.author | Malik, AN | |
dc.contributor.author | Powell, J | |
dc.contributor.author | Lovestone, S | |
dc.contributor.author | Hodges, A | |
dc.contributor.author | AddNeuroMed Consortium | |
dc.date.accessioned | 2017-03-13T10:19:06Z | |
dc.date.issued | 2017-01-07 | |
dc.description.abstract | Although mitochondrial dysfunction is a consistent feature of Alzheimer's disease in the brain and blood, the molecular mechanisms behind these phenomena are unknown. Here we have replicated our previous findings demonstrating reduced expression of nuclear-encoded oxidative phosphorylation (OXPHOS) subunits and subunits required for the translation of mitochondrial-encoded OXPHOS genes in blood from people with Alzheimer's disease and mild cognitive impairment. Interestingly this was accompanied by increased expression of some mitochondrial-encoded OXPHOS genes, namely those residing closest to the transcription start site of the polycistronic heavy chain mitochondrial transcript (MT-ND1, MT-ND2, MT-ATP6, MT-CO1, MT-CO2, MT-C03) and MT-ND6 transcribed from the light chain. Further we show that mitochondrial DNA copy number was unchanged suggesting no change in steady-state numbers of mitochondria. We suggest that an imbalance in nuclear and mitochondrial genome-encoded OXPHOS transcripts may drive a negative feedback loop reducing mitochondrial translation and compromising OXPHOS efficiency, which is likely to generate damaging reactive oxygen species. | en_GB |
dc.description.sponsorship | This work represents independent research part
funded by the InnoMed (Innovative Medicines in Europe) an Integrated
Project funded by the European Union of the Sixth
Framework program priority FP6-2004-LIFESCIHEALTH-5, Alzheimer’s
Research UK, The John and Lucille van Geest Foundation,
the Rosetrees Trust, the National Institute for Health Research
(NIHR) Biomedical Research Centre and Dementia Unit at South
London and Maudsley NHS Foundation Trust and King’s College
London and the National Institute for Health Research University
College London Hospitals Biomedical Research Centre. The views
expressed are those of the author(s) and not necessarily those of
the NHS, the NIHR, or the Department of Health. A. H. receives
support from the Innovative Medicines Initiative Joint Undertaking
under EMIF grant agreement no115372, resources of which are
composed of financial contribution from the European Union’s
Seventh Framework Programme (FP7/2007e2013) and EFPIA
companies in kind contribution. R. D. is supported by awards to
establish the Farr Institute of Health Informatics Research at UCL
Partners, from the Medical Research Council, Arthritis Research
UK, British Heart Foundation, Cancer Research UK, Chief Scientist
Office, Economic and Social Research Council, Engineering and
Physical Sciences Research Council, National Institute for Health
Research, National Institute for Social Care and Health Research,
and Wellcome Trust (grant MR/K006584/1) | en_GB |
dc.identifier.citation | Vol. 53, pp. 36 - 47 | en_GB |
dc.identifier.doi | 10.1016/j.neurobiolaging.2016.12.029 | |
dc.identifier.other | S0197-4580(16)30342-6 | |
dc.identifier.uri | http://hdl.handle.net/10871/26494 | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/28208064 | en_GB |
dc.rights | 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | en_GB |
dc.subject | Alzheimer's disease (AD) | en_GB |
dc.subject | Biomarker | en_GB |
dc.subject | Blood | en_GB |
dc.subject | Gene expression | en_GB |
dc.subject | Mild cognitive impairment (MCI) | en_GB |
dc.subject | Mitochondria | en_GB |
dc.subject | Oxidative phosphorylation (OXPHOS) | en_GB |
dc.title | Mitochondrial genes are altered in blood early in Alzheimer's disease | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2017-03-13T10:19:06Z | |
dc.identifier.issn | 1558-1497 | |
exeter.place-of-publication | United States | en_GB |
dc.description | This is the final version of the article. Available from the publisher via the DOI in this record. | en_GB |
dc.identifier.journal | Neurobiology of Aging | en_GB |
dc.identifier.pmid | 28208064 | |